Actively Recruiting
The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.
Led by Chongqing University Cancer Hospital · Updated on 2023-10-10
188
Participants Needed
1
Research Sites
488 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center single-arm study. The main purpose of this study is to study the efficacy of surgical treatment for patients with locally advanced cervical cancer (FIGO IB3, IIA2-IVA) who still have residual tumor after concurrent radiotherapy and chemotherapy.
CONDITIONS
Official Title
The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients with stage IB3 and IIA2-IVA (FIGO2018) cervical cancer diagnosed as squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma
- Completed standard concurrent chemoradiotherapy including pelvic EBRT, concurrent platinum-containing chemotherapy, and brachytherapy
- Residual cancer confirmed by cervical biopsy or negative biopsy but PET/CT showing SUVmax ≥ 2.5 in residual lesions 4-12 weeks after treatment
- Evaluation by two or more gynecological oncologists with Grade IV operation qualification and multidisciplinary team recommendation for surgery
- ECOG performance status score of 0 or 1
- Expected survival time greater than 6 months
- No absolute contraindications to surgery and good patient compliance
You will not qualify if you...
- Incomplete radiotherapy and chemotherapy or insufficient radiotherapy dose
- Distant metastasis including para-aortic lymph nodes detected by PET/CT or pathology
- Diagnosis of other malignancies within the past five years or requiring treatment
- History of important organ transplantation
- History of immune disease requiring immunosuppressive drugs
- History of serious mental illness or brain functional disorders
- History of drug abuse or current drug use
- Participation in other clinical trials at the same time
- Inability or unwillingness to accept surgical treatment, sign informed consent, or comply with research requirements
- Surgical contraindications including chronic renal insufficiency, liver insufficiency, chronic lung disease with restrictive dysfunction, or cardiac dysfunction not cleared by cardiac physicians
- Inability to understand the research protocol or refusal to sign informed consent
- Other serious concomitant diseases or conditions that endanger health or interfere with the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
Research Team
D
Dongling Zou, PH.D
CONTACT
D
Dongling Zou, PH.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here